Reported Earnings • Apr 09
Full year 2025 earnings released: NT$2.28 loss per share (vs NT$2.20 loss in FY 2024) Full year 2025 results: NT$2.28 loss per share (further deteriorated from NT$2.20 loss in FY 2024). Revenue: NT$48.2m (up 21% from FY 2024). Net loss: NT$164.3m (loss widened 4.3% from FY 2024). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. 공시 • Mar 10
Enimmune Corporation, Annual General Meeting, Jun 09, 2026 Enimmune Corporation, Annual General Meeting, Jun 09, 2026. Location: no,328, chun fu rd., pei tun district, taichung city Taiwan New Risk • Mar 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 22% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (NT$42m revenue, or US$1.3m). Market cap is less than US$100m (NT$1.36b market cap, or US$43.3m). New Risk • Aug 27
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.8% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Revenue is less than US$5m (NT$42m revenue, or US$1.4m). Market cap is less than US$100m (NT$1.70b market cap, or US$55.5m). 공시 • Mar 12
Enimmune corporation, Annual General Meeting, Jun 17, 2025 Enimmune corporation, Annual General Meeting, Jun 17, 2025, at 09:00 Taipei Standard Time. Location: no,328, chun fu rd., pei tun district, taichung city Taiwan New Risk • Mar 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (6.5% average weekly change). Revenue is less than US$5m (NT$51m revenue, or US$1.5m). Market cap is less than US$100m (NT$1.84b market cap, or US$55.9m). New Risk • Feb 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Revenue is less than US$5m (NT$51m revenue, or US$1.5m). Market cap is less than US$100m (NT$1.89b market cap, or US$57.2m). New Risk • Sep 01
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Shareholders have been diluted in the past year (9.5% increase in shares outstanding). Revenue is less than US$5m (NT$51m revenue, or US$1.6m). Market cap is less than US$100m (NT$2.52b market cap, or US$78.7m). Reported Earnings • Aug 18
Second quarter 2024 earnings released: NT$0.58 loss per share (vs NT$0.59 loss in 2Q 2023) Second quarter 2024 results: NT$0.58 loss per share. Net loss: NT$39.6m (loss widened 2.0% from 2Q 2023). New Risk • Jul 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Revenue is less than US$5m (NT$43m revenue, or US$1.3m). Market cap is less than US$100m (NT$2.89b market cap, or US$88.2m). 공시 • Mar 22
Enimmune corporation, Annual General Meeting, Jun 12, 2024 Enimmune corporation, Annual General Meeting, Jun 12, 2024. Reported Earnings • Mar 14
Full year 2023 earnings released: NT$3.40 loss per share (vs NT$3.88 loss in FY 2022) Full year 2023 results: NT$3.40 loss per share (improved from NT$3.88 loss in FY 2022). Net loss: NT$223.7m (loss narrowed 9.8% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. New Risk • Feb 27
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (NT$109m revenue, or US$3.5m). Market cap is less than US$100m (NT$2.45b market cap, or US$77.6m). New Risk • Aug 13
New minor risk - Revenue size The company makes less than US$5m in revenue. Total revenue: NT$109m (US$3.4m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risks Revenue is less than US$5m (NT$109m revenue, or US$3.4m). Market cap is less than US$100m (NT$2.85b market cap, or US$89.3m). New Risk • Jul 23
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.13b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$3.13b market cap, or US$99.7m). Reported Earnings • Apr 23
Full year 2022 earnings released: NT$3.88 loss per share (vs NT$0.79 loss in FY 2021) Full year 2022 results: NT$3.88 loss per share (further deteriorated from NT$0.79 loss in FY 2021). Revenue: NT$188.4m (up 72% from FY 2021). Net loss: NT$248.0m (loss widened 425% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • May 02
Full year 2021 earnings released: NT$0.79 loss per share (vs NT$1.40 loss in FY 2020) Full year 2021 results: NT$0.79 loss per share (up from NT$1.40 loss in FY 2020). Revenue: NT$109.8m (up 380% from FY 2020). Net loss: NT$47.2m (loss narrowed 37% from FY 2020). Over the last 3 years on average, earnings per share has increased by 34% per year whereas the company’s share price has increased by 35% per year. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. 공시 • Apr 02
Enimmune corporation, Annual General Meeting, Jun 21, 2022 Enimmune corporation, Annual General Meeting, Jun 21, 2022. Reported Earnings • Apr 25
Full year 2020 earnings released: NT$1.40 loss per share (vs NT$1.29 loss in FY 2019) Full year 2020 results: Net loss: NT$74.5m (loss widened 31% from FY 2019). Is New 90 Day High Low • Feb 20
New 90-day high: NT$51.70 The company is up 12% from its price of NT$46.00 on 20 November 2020. The Taiwanese market is up 18% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 12% over the same period. Is New 90 Day High Low • Dec 05
New 90-day low: NT$42.75 The company is down 32% from its price of NT$62.60 on 04 September 2020. The Taiwanese market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 8.0% over the same period. Is New 90 Day High Low • Nov 12
New 90-day low: NT$43.10 The company is down 32% from its price of NT$63.50 on 14 August 2020. The Taiwanese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period. Is New 90 Day High Low • Sep 30
New 90-day low: NT$52.10 The company is down 43% from its price of NT$91.00 on 02 July 2020. The Taiwanese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 6.0% over the same period.